Why is pancreatic cancer often diagnosed late?

The pancreas sits deep in the abdomen, and tumours growing in the body or tail of the gland often cause no symptoms until they are large or have spread. Jaundice — which can prompt early investigation — only occurs when a tumour grows near the bile duct in the head of the pancreas. Most people have no reliable screening test available. As a result, roughly 80–85% of people are diagnosed when the cancer has already spread beyond the pancreas, which limits treatment options.

What is the difference between PDAC and other pancreatic cancers?

Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90–95% of pancreatic cancers and arises from the cells lining the pancreatic ducts. Less common types include pancreatic neuroendocrine tumours (PNETs), which arise from hormone-producing cells and generally have a better prognosis, and rare types such as acinar cell carcinoma. This guide focuses mainly on PDAC, which is what most people mean when they refer to pancreatic cancer.

Can pancreatic cancer be removed by surgery?

Surgery with the goal of removing all visible cancer (resection) is the only curative-intent treatment currently available. Unfortunately, only about 15–20% of people are diagnosed when the cancer is confined enough to be considered for surgery. The most common procedure for pancreatic head tumours is the Whipple operation (pancreaticoduodenectomy), a technically demanding surgery. Even after successful resection, the cancer frequently recurs, which is why chemotherapy is given after surgery to reduce this risk.

What is KRAS and why does it matter in pancreatic cancer?

KRAS is a gene that encodes a protein involved in signalling cells to grow. In more than 90% of pancreatic cancers, a mutation in KRAS locks this signalling switch permanently in the "on" position, driving tumour growth. KRAS mutations were identified in the 1980s but remained effectively undruggable for decades because the protein lacked suitable binding pockets. Recent advances have produced the first KRAS-targeting drugs showing meaningful clinical benefit in Phase 3 trials — a significant shift after decades of limited progress.

What is biomarker testing and should everyone with pancreatic cancer have it?

Biomarker testing analyses the genetic and molecular profile of the tumour (and sometimes blood) to identify changes that might be targeted by specific drugs, or that predict how the cancer will behave. For people with metastatic or advanced pancreatic cancer, most major guidelines now recommend comprehensive molecular profiling (including NGS of tumour tissue) and germline testing for BRCA1/2 and other hereditary mutations. Actionable findings (such as BRCA2 mutations, MSI-high status, or NTRK fusions) are less common in pancreatic cancer than in some other tumour types, but identifying them can meaningfully change treatment options.

What is the prognosis for pancreatic cancer?

Prognosis varies substantially by stage at diagnosis. The overall 5-year survival rate is approximately 12–13% (NCI SEER data), which reflects the fact that most people are diagnosed late. When the cancer is confined to the pancreas (localised, stage I), 5-year survival is around 37–44%. For metastatic disease (stage IV), it falls to approximately 3%. These are population averages and do not predict what will happen to any individual — survival depends on many factors including tumour biology, fitness, treatment response, and access to clinical trials.

Pancreatic Cancer: Symptoms, Diagnosis, and Treatment

Pancreatic cancer is one of the most difficult cancers to treat, partly because it rarely causes noticeable symptoms in its early stages and partly because of its underlying biology. About 80–85% of people are diagnosed after the cancer has spread beyond the pancreas, when treatment options are more limited. Even so, treatment is advancing — slowly but meaningfully — and options have expanded in recent years.

This guide covers what pancreatic cancer is, who is at risk, what symptoms to watch for, how it is diagnosed and staged, and what current treatments can and cannot offer.

What Is the Pancreas?

The pancreas is a gland that sits behind the stomach in the upper abdomen. It has two main roles:

Exocrine function: Producing digestive enzymes that flow into the small intestine via the pancreatic duct to help break down food.
Endocrine function: Producing hormones, including insulin and glucagon, that regulate blood sugar.

Most pancreatic cancers — roughly 90–95% — arise from the exocrine cells lining the ducts. This type is called pancreatic ductal adenocarcinoma (PDAC). When people refer to “pancreatic cancer,” they usually mean PDAC. A rarer type, pancreatic neuroendocrine tumours (PNETs), arises from the hormone-producing cells and typically behaves differently.

Who Is at Risk?

Pancreatic cancer becomes more common with age. Most diagnoses occur in people over 65. Other risk factors include:

Smoking — one of the strongest modifiable risk factors; smokers have roughly twice the risk of non-smokers
Long-standing type 2 diabetes — increases risk; new-onset diabetes in an older, non-obese person can sometimes be an early sign of pancreatic cancer
Chronic pancreatitis — long-term inflammation of the pancreas substantially increases lifetime risk
Obesity — associated with modestly elevated risk
Family history — having a first-degree relative with pancreatic cancer increases risk
Inherited gene variants — germline mutations in BRCA2, PALB2, ATM, STK11 (Peutz-Jeghers syndrome), and Lynch syndrome genes are found in approximately 5–10% of people with pancreatic cancer

If you have a strong family history or a known hereditary cancer syndrome, genetic counselling and surveillance may be appropriate — discuss this with your doctor.

Symptoms

Pancreatic cancer frequently causes no symptoms until it is locally advanced or has spread. When symptoms do occur, they depend partly on where in the pancreas the tumour is growing.

Jaundice (yellowing of the skin or whites of the eyes) is one of the more recognisable symptoms, occurring when a tumour in the head of the pancreas blocks the bile duct. Associated features include pale or greasy stools, dark urine, and itchy skin. Jaundice tends to prompt earlier investigation, but not all tumours arise near the bile duct.

Abdominal and back pain is common — typically a dull ache in the upper abdomen that may radiate through to the middle of the back. This happens when the tumour presses on surrounding structures or nerves.

Unexplained weight loss and loss of appetite — often significant weight loss without a clear cause — are among the most common presenting symptoms.

New-onset diabetes or sudden worsening of previously controlled diabetes in a person over 50 who is not overweight should prompt investigation for pancreatic cancer. Diabetes can be caused directly by a tumour damaging the insulin-producing cells of the pancreas.

Other symptoms may include fatigue, nausea, and a feeling of fullness after eating little.

None of these symptoms is specific to pancreatic cancer — many are caused by other, more common conditions. But symptoms that are new, persistent, or unexplained — especially jaundice — warrant prompt medical evaluation.

Diagnosis

Initial investigation

If a doctor suspects pancreatic cancer based on symptoms, blood tests (including a CA19-9 tumour marker and liver function tests), and sometimes clinical examination, they will arrange imaging.

Contrast-enhanced CT scan of the abdomen and pelvis is the primary imaging test. It can identify a tumour, assess whether it involves nearby blood vessels, and look for spread to the liver or other organs.

MRI and magnetic resonance cholangiopancreatography (MRCP) are sometimes used alongside CT or when the CT result is inconclusive. MRCP provides detailed images of the bile duct and pancreatic duct.

Endoscopic ultrasound (EUS) uses a small ultrasound probe passed via an endoscope into the stomach, allowing very close imaging of the pancreas. EUS can also be used to take a tissue sample (fine-needle aspiration biopsy) directly from the tumour, which is often needed to confirm the diagnosis before treatment starts.

Confirming the diagnosis

A biopsy — laboratory examination of tumour tissue — is typically required before starting treatment (with exceptions, usually when surgery is planned upfront for a highly suspicious lesion). Tissue can also be obtained by ERCP (endoscopic retrograde cholangiopancreatography), which allows bile duct access, or occasionally by CT-guided biopsy.

The CA19-9 blood test is sometimes elevated in pancreatic cancer but has significant limitations — it can be normal in some cancers and elevated in benign conditions. It is not a reliable screening test, but it is useful for monitoring treatment response once a diagnosis is established.

Staging

Staging uses the TNM (tumour, nodes, metastasis) system:

Stage	Meaning
I	Confined to the pancreas
II	Extended beyond pancreas but no major vessel involvement or limited lymph node spread
III	Involves major blood vessels or extensive lymph nodes; unresectable locally advanced
IV	Spread to distant organs (liver, lungs, peritoneum)

Staging determines the treatment approach. Surgeons also classify tumours as resectable, borderline resectable, or locally advanced unresectable based on involvement of nearby major blood vessels.

Treatment

Surgery

Surgery offering the possibility of cure is only feasible for approximately 15–20% of people at diagnosis — those with disease confined to the pancreas or with borderline resectable disease that may be converted with chemotherapy.

Whipple procedure (pancreaticoduodenectomy) is the main operation for cancers in the head of the pancreas. It involves removing the head of the pancreas, the duodenum, the gallbladder, the lower bile duct, and part of the stomach, then reconstructing the digestive tract. It is a major, lengthy surgery performed at specialist centres with high surgical volume.

Distal pancreatectomy removes the body and tail of the pancreas (often with the spleen) for cancers in those locations.

Adjuvant chemotherapy is recommended after surgery for most patients to reduce the risk of recurrence. Regimens include mFOLFIRINOX (modified FOLFIRINOX) or gemcitabine plus capecitabine, based on clinical evidence showing improved survival compared with surgery alone.

For borderline resectable disease, chemotherapy — sometimes with radiotherapy — is often given before surgery (neoadjuvant treatment) to attempt to shrink the tumour and improve the chance of achieving clear surgical margins.

Chemotherapy

For people with advanced or metastatic pancreatic cancer who are fit for treatment:

FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) or mFOLFIRINOX is typically the preferred first-line regimen for people with good performance status. It extends survival compared with gemcitabine alone but requires regular IV infusions and has substantial side effects.
Gemcitabine plus nab-paclitaxel is an alternative first-line regimen, particularly for those who cannot tolerate FOLFIRINOX. It is given intravenously.

When first-line chemotherapy stops working, second-line options are limited and have historically offered modest additional survival benefit. This is the setting where new targeted agents are being studied.

Targeted therapy and biomarker-driven treatment

Most standard chemotherapy works by killing rapidly dividing cells regardless of molecular type. Targeted therapies aim at specific molecular changes in the cancer.

BRCA1/2 and PALB2 mutations: People with germline BRCA1 or BRCA2 mutations whose metastatic cancer has been treated with platinum-based chemotherapy may be eligible for olaparib (a PARP inhibitor) as maintenance therapy. Evidence from the POLO trial showed olaparib prolonged progression-free survival compared with placebo in this population.

KRAS mutations (investigational): More than 90% of pancreatic cancers carry KRAS mutations. Drugs targeting KRAS have historically been unavailable, but Phase 3 trial results published in the New England Journal of Medicine in May 2026 showed that daraxonrasib — an oral RAS(ON) inhibitor — roughly doubled median overall survival compared with chemotherapy in previously treated metastatic PDAC. As of June 2026, daraxonrasib has not received regulatory approval, though it holds FDA Breakthrough Therapy designation and an expanded access programme has been initiated. See: Why Scientists Thought Pancreatic Cancer Was ‘Undruggable’ — And What Changed.

MSI-H / mismatch repair deficiency: A very small proportion of pancreatic cancers (under 1%) are MSI-high, which makes them eligible for pembrolizumab (an immune checkpoint inhibitor). Identifying this rare subtype requires molecular testing.

NTRK fusions and other rare alterations: Comprehensive molecular profiling may identify other rare actionable mutations for which approved therapies exist.

Biomarker testing

Most major oncology guidelines now recommend:

Comprehensive molecular profiling of tumour tissue (next-generation sequencing) for patients with metastatic or advanced disease
Germline genetic testing for BRCA1/2 and other hereditary mutations for all patients with pancreatic cancer

Finding an actionable mutation is not guaranteed — many pancreatic cancers do not carry currently targetable alterations beyond KRAS, and KRAS-targeting drugs are still investigational for most patients. But molecular profiling is important because it can identify the minority of patients who may benefit from specific treatments or clinical trials.

Clinical trials

For people with pancreatic cancer, participation in clinical trials is often a meaningful option — particularly after first-line treatment. Trials evaluating KRAS inhibitors, combination immunotherapy, novel chemotherapy approaches, and other strategies are ongoing. Your oncologist or a specialist pancreatic cancer centre can advise on eligibility.

Prognosis

Prognosis varies substantially by stage at diagnosis:

Stage	Approximate 5-year survival
Localised (stage I)	~37–44%
Regional spread (stage II–III)	~14–18%
Distant metastases (stage IV)	~3%
Overall	~12–13%

Source: NCI SEER database.

These are population statistics drawn from large datasets. They do not predict what will happen to any individual. Survival depends on many factors: tumour biology, performance status, access to specialist treatment and clinical trials, response to therapy, and comorbidities.

Prognosis for pancreatic cancer has improved slowly over recent decades, partly through chemotherapy advances and partly through better surgical care. The emergence of biomarker-driven treatments — particularly KRAS inhibitors — may improve outcomes further, though much of that evidence is still developing.

If You Have Received a Diagnosis

A pancreatic cancer diagnosis is frightening, and the prognosis statistics are genuinely sobering. A few things are worth knowing:

Seek care at a specialist centre with a dedicated pancreatic cancer multidisciplinary team. Volume and experience matter in both surgery and medical oncology.
Ask about clinical trials early — not just as a last resort. Trials are often available earlier in the treatment course, and access to investigational agents may be most useful before standard options are exhausted.
Ask for molecular profiling and germline testing if not already offered. Understanding your tumour’s biology matters.
Palliative and supportive care is not only for end-of-life. Symptom management, nutritional support, and pain control are integral to treatment from the start.
Patient advocacy organisations such as PanCAN offer patient services, clinical trial matching, and peer support.

FAQ

Q: What are the warning signs of pancreatic cancer? Jaundice (yellowing of skin or eyes), unexplained weight loss, upper abdominal pain radiating to the back, and new-onset diabetes in an older, non-obese person. These symptoms are not unique to pancreatic cancer but warrant prompt evaluation.

Q: Why is pancreatic cancer so often found late? The pancreas is deep in the abdomen, and most tumours cause no symptoms until locally advanced or spread. There is currently no reliable screening test for the general population.

Q: Is pancreatic cancer always fatal? No — though outcomes are serious for most patients. Around 15–20% of people have disease suitable for surgical resection, and some of these patients achieve long-term survival. Early-stage disease has a meaningfully better prognosis than metastatic disease.

Q: What is the Whipple operation? Pancreaticoduodenectomy (the Whipple procedure) is a major surgical operation to remove the head of the pancreas, duodenum, gallbladder, and lower bile duct. It is the main curative-intent surgery for cancers in the head of the pancreas and is performed at specialist centres.

Q: What is biomarker testing and who should have it? Biomarker testing analyses the molecular profile of the tumour to identify changes that may be targeted by specific drugs or that make patients eligible for clinical trials. For metastatic or advanced pancreatic cancer, comprehensive molecular profiling and germline genetic testing are recommended by major guidelines.

Q: What is KRAS and why does it matter? KRAS is a gene mutated in more than 90% of pancreatic cancers. It drives tumour growth by locking a cell-signalling switch permanently “on.” KRAS was historically considered undruggable, but 2026 Phase 3 trial results showed a KRAS-targeting drug (daraxonrasib) roughly doubled survival compared with chemotherapy — a significant development after decades of limited progress.

Q: Should I ask about clinical trials? Yes — particularly if you have been diagnosed with advanced or metastatic disease, or after first-line chemotherapy. Discuss trial eligibility with your oncologist early. Major pancreatic cancer centres often have access to trials that may not be available in smaller settings.